PXD LIMITED is a specialized discovery company focused on biotechnology and related advancements within the medical practice sector. Established in 2011 as a limited liability company, PXD Ltd operates from its headquarters at The Biosphere Draymans Way in Newcastle upon Tyne, NE4 5BX. The company’s core activities center around research and experimental development utilizing advanced biotechnological methodologies. PXD Ltd specializes in identifying novel therapeutic targets and developing innovative diagnostic tools, with a particular emphasis on cardiovascular health and neurological disorders. Their expertise encompasses preclinical studies and clinical trials supporting the advancement of medical treatment options. PXD Ltd's strategic focus is on uncovering new avenues for pharmaceutical development and improving patient outcomes through targeted research. They actively monitor competitor activity within the medical practice landscape to identify emerging trends, technological shifts, and market opportunities. The company has a strong international presence, indicating a commitment to global collaboration and innovation. As a Skilled Worker visa holder, PXD Ltd is currently rated as a worker (A rating) with a significant focus on strategic research and development. The company’s stock symbol is PDX.

PXD LIMITED is a specialized discovery company focused on biotechnology and related advancements within the medical practice sector. Established in 2011 as a limited liability company, PXD Ltd operates from its headquarters at The Biosphere Draymans Way in Newcastle upon Tyne, NE4 5BX. The company’s core activities center around research and experimental development utilizing advanced biotechnological methodologies. PXD Ltd specializes in identifying novel therapeutic targets and developing innovative diagnostic tools, with a particular emphasis on cardiovascular health and neurological disorders. Their expertise encompasses preclinical studies and clinical trials supporting the advancement of medical treatment options. PXD Ltd's strategic focus is on uncovering new avenues for pharmaceutical development and improving patient outcomes through targeted research. They actively monitor competitor activity within the medical practice landscape to identify emerging trends, technological shifts, and market opportunities. The company has a strong international presence, indicating a commitment to global collaboration and innovation. As a Skilled Worker visa holder, PXD Ltd is currently rated as a worker (A rating) with a significant focus on strategic research and development. The company’s stock symbol is PDX.